機関投資家はアッヴィの株式保有を増やし、業績予想を上回り、増収となりました。 Institutional investors boost holdings in AbbVie, which beat earnings estimates and raised revenue.

企業投資家は 市場資本額321290億ドルの 製薬会社AbbVie Inc.の 持分を増加させました Institutional investors like Guerra Advisors and CFM Wealth Partners have increased their holdings in AbbVie Inc., a pharmaceutical company with a market cap of $321.29 billion. AbbVieの株式は211.29の価格目標で"モデレート・バイヤー"の評価を受けた. AbbVie's stock received a "Moderate Buy" rating with a price target of $211.29. 同社は1株あたり2.46円の収益を報告し,当該総額は0.06ドルと見積もられ,その収入は年間8.4%増加した. The company reported earnings of $2.46 per share, beating estimates by $0.06, and its revenue increased by 8.4% year-over-year. AbbVieの製品ラインには,Humira, Skyrizi,Rinvoqを含む. AbbVie's product line includes Humira, Skyrizi, and Rinvoq. 会社はまた 8月15日に支払われる 株当たり1.64ドルの四半期配当を 宣言しました The company also declared a quarterly dividend of $1.64 per share, to be paid on August 15th.